Literature DB >> 23437846

Emergency contraception.

Kristina Gemzell-Danielsson1, Thomas Rabe, Linan Cheng.   

Abstract

There have been numerous attempts to control fertility after unprotected sexual intercourse (UPSI). From very bizarre methods like the vaginal application of Coca Cola to the more serious attempts using calcium antagonists influencing fertility parameters in sperm to hormonal methods or intrauterine devices. So far, hormonal methods preventing or delaying ovulation have proved to be the most popular starting with the combination of ethinyl estradiol and levonorgestrel (LNG), known as the Yuzpe regimen. The first dose had to be taken within 72 hours of UPSI, a second one 12 hours later. Later on, LNG alone, at first in a regimen similar to the Yuzpe method (2 × 0.75 mg 12 hours apart) showed to be more successful, eventually resulting in the development of a 1.5 mg LNG pill that combined good efficacy with a high ease of use. Several efficacious and easy to use methods for emergency contraception (EC) are available on the market today with the most widely spread being LNG in a single dose of 1.5 mg (given as one tablet of 1.5 mg or 2 tablets of 0.75 mg each) for administration up to 3 days (according to WHO up to 5 days) after UPSI. Its limitations are the non-optimal efficacy which is decreasing the later the drug is taken and the fact that it is only approved for up to 72 hours after UPSI. This regimen has no effect on the endometrium, corpus luteum function and implantation, is not abortive and don't harm the fetus if accidentally taken in early pregnancy. It has no impact on the rate of ectopic pregnancies. It has become the standard method used up to this day in most countries. Since the mid 1970s copper IUDs have been used for EC, which show a high efficacy. Their disadvantages lie in the fact that EC is considered an off label use for most IUDs (not for the GynFix copper IUD in the European Union) and that they might not be acceptable for every patient. Furthermore IUD-insertion is an invasive procedure and it is required trained providers and sterilized facilities. Mifepristone in the dosages of 10 or 25 mg is used with good results as an emergency contraceptive in China for up to 120 hours after UPSI, but has never received any significant consideration in Western countries. While high doses of mifepristone has an effect on endometrial receptivity and will inhibit ovulation if given in the follicular phase and prevent implantation if given in the early luteal phase, low doses such as 10 mg has no impact on the endometrium. Mifepristone does not increase the rate of ectopic pregnancies. The most recent development is the approval of the selective progesterone receptor modulator ulipristal acetate (UPA) in the dosage of 30 mg for EC up to 5 days after UPSI, combining the safe and easy application of the single dose LNG pill with an even higher efficacy. It has shown to be more efficacious than LNG and can be used for up to 120 hours after UPSI; the difference in efficacy is highest for 0-24 hours, followed by 0-72 hours following UPSI. No VTE has been reported following UPA-administration or any progesterone receptor modulator. No effect on endometrium, corpus luteum function and implantation has been observed with doses used for EC. Independent of the substance it should be noted that, if there is a choice, the intake of an oral emergency contraceptive pill should happen as soon as possible after the risk situation. A pre-existing pregnancy must be excluded. Possible contraindications and drug interactions must be considered according to the individual special product informations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23437846     DOI: 10.3109/09513590.2013.774591

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  9 in total

Review 1.  Novel contraceptive targets to inhibit ovulation: the prostaglandin E2 pathway.

Authors:  Diane M Duffy
Journal:  Hum Reprod Update       Date:  2015-05-29       Impact factor: 15.610

2.  Hormonal anticonception anno 2013: a clinician's view.

Authors:  M Dhont; V Verhaeghe
Journal:  Facts Views Vis Obgyn       Date:  2013

3.  Association between levonorgestrel emergency contraception and the risk of ectopic pregnancy: a multicenter case-control study.

Authors:  Jian Zhang; Cheng Li; Wei-Hong Zhao; Xiaowei Xi; Shu-Jun Cao; Hua Ping; Guo-Juan Qin; Linan Cheng; He-Feng Huang
Journal:  Sci Rep       Date:  2015-02-12       Impact factor: 4.379

Review 4.  Clinical Pharmacology of Hormonal Emergency Contraceptive Pills.

Authors:  Celia M J Matyanga; Blessing Dzingirai
Journal:  Int J Reprod Med       Date:  2018-10-04

5.  The attitudes of Korean physicians toward emergency contraceptive pills: regarding women's access and rescheduling.

Authors:  Eun Sil Lee; Chong A Lee; Jee Hee Lee; Bo Ra Park; Imsoon Lee
Journal:  Obstet Gynecol Sci       Date:  2019-04-25

6.  Reduced prevalence of chronic tubal inflammation in tubal pregnancies after levonorgestrel emergency contraception failure.

Authors:  Cheng Li; Chun-Xia Meng; Lu-Lu Sun; Wei-Hong Zhao; Mei Zhang; Jian Zhang; Linan Cheng
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-03-31       Impact factor: 2.890

7.  Contraceptive Use and the Risk of Ectopic Pregnancy: A Multi-Center Case-Control Study.

Authors:  Cheng Li; Wei-Hong Zhao; Chun-Xia Meng; Hua Ping; Guo-Juan Qin; Shu-Jun Cao; Xiaowei Xi; Qian Zhu; Xiao-Cui Li; Jian Zhang
Journal:  PLoS One       Date:  2014-12-10       Impact factor: 3.240

8.  Association between knowledge about levonorgestrel emergency contraception and the risk of ectopic pregnancy following levonorgestrel emergency contraception failure: a comparative survey.

Authors:  Duo Zhang; Ming-Xing Yan; Jue Ma; Wei Xia; Rui-Hong Xue; Jing Sun; Jian Zhang
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-01-08       Impact factor: 2.890

Review 9.  Mechanism of Action of Ulipristal Acetate for Emergency Contraception: A Systematic Review.

Authors:  Elena Rosato; Manuela Farris; Carlo Bastianelli
Journal:  Front Pharmacol       Date:  2016-01-12       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.